Yu Ping, Rowley Donald A, Fu Yang-Xin, Schreiber Hans
Department of Pathology and Committee on Immunology, The University of Chicago, 5831 S. Ellis Avenue, Chicago, Il 60637, USA.
Curr Opin Immunol. 2006 Apr;18(2):226-31. doi: 10.1016/j.coi.2006.01.004. Epub 2006 Feb 3.
Well-established solid tumors (at least 14 days old and >1cm in average diameter) are extremely difficult to eradicate immunologically in mice. Most cancer patients that seek medical attention bear primary or metastatic tumors that have grown for longer and that are larger than the tumors we call established. Therefore, focusing research on the problems of rejecting well-established mouse tumors might help in the development of novel concepts and protocols for destroying tumors in patients. A particular problem with established cancers is that even when treatments induce temporary regression, cancer often recurs. Recent studies suggest that manipulation of the stromal microenvironment of these tumors can induce immune recognition and regression. Furthermore, targeting cancer cells as well as tumor stroma for immune destruction might be needed to prevent recurrence.
成熟的实体瘤(至少14天且平均直径>1厘米)在小鼠体内极难通过免疫方式根除。大多数寻求医疗救治的癌症患者所携带的原发性或转移性肿瘤生长时间更长、体积也比我们所说的成熟肿瘤更大。因此,将研究重点放在攻克成熟小鼠肿瘤的问题上,可能有助于开发新的理念和方案来摧毁患者体内的肿瘤。成熟癌症的一个特殊问题是,即使治疗能诱导肿瘤暂时消退,癌症往往也会复发。最近的研究表明,对这些肿瘤的基质微环境进行调控可诱导免疫识别和肿瘤消退。此外,可能需要同时针对癌细胞和肿瘤基质进行免疫破坏,以防止复发。